Continuing Treatment Not Beneficial After 5 Years of Bisphosphonates
No difference seen in cumulative incidence of hip fracture for continuing therapy for two, five additional years versus discontinuing
No difference seen in cumulative incidence of hip fracture for continuing therapy for two, five additional years versus discontinuing
Psychiatric, orthopedic, and sleep issues most commonly cited in a Reddit forum
Vosoritide is an investigational analogue of C-type natriuretic peptide.
For those with previous vertebral fracture, major osteoporotic fractures increased with holidays >12 months.
Exploratory analysis reveals total hip/knee replacement rate reduced with canakinumab vs placebo.
Increase in risk with long delay of subsequent doses not significant for composite of all fracture types
Combined oral contraceptives linked to improvement in bone mass, similar to that with high-dose HT.
The FDA as approved Crysvita® (burosumab-twza; Ultragenyx) for the treatment of fibroblast growth factor 23 (FGF23)-related hypophosphatemia in tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in patients aged ≥2 years.
Small but significant risk seen for upper-limb and lower-limb fractures
The Endocrine Society has issued an update to the organization’s 2019 clinical practice guideline on pharmacologic management of osteoporosis to include romosozumab.